

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	Remove Age Concern England from patient/carer group consultees.	Age Concern		Removed	Completed as per the specific organisations request.
2.	Remove British Ethnic Health Awareness Foundation (BEHAF) from patient/carer group consultees.	NICE Secretariat		Removed	British Ethnic Health Awareness Foundation (BEHAF) has been removed from the Charity Commission records and therefore doesn't meet the inclusion criteria.

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for technology appraisal of dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion

Issue date: July 2010

3.	Remove Confederation of Indian Organisations from patient/carer group consultees.	NICE Secretariat		Removed	Confederation of Indian Organisations have now closed, and therefore been removed from the matrix.
4.	Remove Help the Aged from patient/carer group consultees.	Help the Aged		Removed	Completed as per the specific organisations request.
5.	Remove Age Concern Cymru from general group commentators.	Age Concern		Removed	Completed as per the specific organisations request.
6.	Add Commissioning Support Appraisals Service to general group commentators.	NICE Secretariat		Added	Commissioning Support Appraisals Service meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a general group commentator.
7.	Add Care Quality Commission to general group commentators.	NICE Secretariat		Added	Care Quality Commission meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a general group commentator.

8.	We believe that BMS and Roche should not be listed as commentators as the products that they manufacture are not licensed for the treatment of macular oedema following RVO.	Allergan	Noted	Discussed at sign-off. These products have been included in the scope as comparators. In an appraisal, comparators do not need to be licensed. Therefore these manufacturers should remain on the matrix.
----	--	----------	-------	---